<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118484</article-id><article-id pub-id-type="publisher-id">ACM-44288</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_39693698.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  传统肿瘤标记物预测胃癌新辅助化疗疗效的研究
  Study on Prediction of Neoadjuvant Chemotherapy Efficacy of Traditional Tumor Markers in Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>传绪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>熙勋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>金晨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>翼飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姚</surname><given-names>增武</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>立新</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属烟台毓璜顶医院胃肠外一科，山东 烟台 </addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3333</fpage><lpage>3348</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：分析传统肿瘤标记物预测胃癌新辅助化疗疗效的研究。方法：回顾性分析90例接受新辅助化疗胃癌患者的临床病理资料，记录患者新辅助化疗前后CEA、CA199、CA724的表达水平，并在新辅助化疗和手术结束后根据recist1.1评分标准将患者分为疾病控制组(CR + PR + SD)和疾病进展组(PD)，根据Ryan标准将患者分为病理完全退缩组(pCR)和非病理完全退缩组(Non-pCR)。分别分析CEA、CA199、CA724在新辅助化疗前水平和化疗前后变化量对胃癌新辅助化疗疗效和病理完全缓解率的预测。结果：CEA阳性率与肿瘤的分化程度、淋巴结转移、疾病进展有关。CA724与肿瘤大小、TNM分期等因素相关。3种肿瘤标记物联合检测阳性与淋巴结转移、分化程度密切相关。CEA化疗前高水平对疾病进展可能具有预测作用(AUC = 682, 95%CI: 0.549~0.815, P = 0.010)，最大化该试验的灵敏度(52.2%)和特异性(83.6%)的临界值为17.65 ng/ml。新辅助化疗后3种传统肿瘤标记物的水平较化疗前下降，CA724的降低量可能具有预测疾病控制的作用(AUC = 0.749, 95%CI: 0.550~0.947, P = 0.047)，同时使试验的灵敏度(56.0%)和特异性(85.7%)最大化的最佳截止值降低了64.0%。CA199化疗前水平对非病理完全缓解可能具有预测作用(AUC = 0.740, 95%CI: 0.538~0.942, P = 0.036)，最大化该试验的灵敏度(74.7%)和特异性(85.7%)的临界值为6.89 U/ml。CA724的降低量对病理完全缓解可能具有预测作用(AUC = 0.933, 95%CI: 0.839~1.000, P = 0.043)，同时使试验的灵敏度(100%)和特异性(90.0%)最大化的最佳截止值降低了90.6%。结论：CEA、CA199、CA724可能对胃癌新辅助化疗的疗效和病理反应具有预测作用，对于胃癌的新辅助化疗可能具有指导作用。
   Objective: To analyze the efficacy of traditional tumor markers in predicting neoadjuvant chemotherapy for gastric cancer. Methods: The clinicopathological data of 90 patients with gastric cancer who received neoadjuvant chemotherapy were retrospectively analyzed. The expression levels of CEA, CA199, and CA724 before and after neoadjuvant chemotherapy were recorded. After neoadjuvant chemotherapy and surgery, the patients were divided according to the recest1.1 scoring standard. For the disease control group (CR + PR + SD) and the disease progression group (PD), patients were divided into pathological complete remission group (pCR) and non-pathological complete remission group (Non-pCR) according to Ryan standard. The levels of CEA, CA199, and CA724 before and after neoadjuvant chemotherapy were analyzed respectively to predict the efficacy of neoadjuvant chemotherapy and pathological complete remission rate for gastric cancer. Results: The positive rate of CEA is related to the degree of tumor differentiation, lymph node metastasis, and disease progression. CA724 is related to tumor size, TNM stage and other factors. The positive combined detection of the three tumor markers is closely related to the degree of lymph node metastasis and differentiation. The high level of CEA before chemotherapy may have a predictive effect on disease progression (AUC = 682, 95%CI: 0.549~0.815, P = 0.010), maximizing the critical value of the sensitivity (52.2%) and specificity (83.6%) of the test, it is 17.65 ng/ml. The levels of the three traditional tumor markers after neoadjuvant chemotherapy were lower than before chemotherapy. The reduction of CA724 may have a predictive effect on disease control (AUC = 0.749, 95%CI: 0.550~0.947, P = 0.047). The optimal cutoff value for maximizing sensitivity (56.0%) and specificity (85.7%) is reduced by 64.0%. The level of CA199 before chemotherapy may have a predictive effect on non-pathological complete remission (AUC = 0.740, 95%CI: 0.538~0.942, P = 0.036), maximizing the sensitivity (74.7%) and specificity (85.7%) of the test, the value is 6.89 U/ml. The reduction of CA724 may have a predictive effect on pathological complete remission (AUC = 0.933, 95%CI: 0.839~1.000, P = 0.043), while maximizing the sensitivity (100%) and specificity (90.0%) of the test, the best cut-off value is reduced by 90.6%. Conclusion: CEA, CA199, and CA724 may have predictive effects on the efficacy and pathological response of neoadjuvant chemotherapy for gastric cancer, and may have a guiding role for neoadjuvant chemotherapy for gastric cancer.
 
</p></abstract><kwd-group><kwd>胃癌，新辅助化疗，疗效评估，CEA，CA199，CA724, Gastric Cancer</kwd><kwd> Neoadjuvant Chemotherapy</kwd><kwd> Evaluations of Response</kwd><kwd> CEA</kwd><kwd> CA199</kwd><kwd> CA724</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析传统肿瘤标记物预测胃癌新辅助化疗疗效的研究。方法：回顾性分析90例接受新辅助化疗胃癌患者的临床病理资料，记录患者新辅助化疗前后CEA、CA199、CA724的表达水平，并在新辅助化疗和手术结束后根据recist1.1评分标准将患者分为疾病控制组(CR + PR + SD)和疾病进展组(PD)，根据Ryan标准将患者分为病理完全退缩组(pCR)和非病理完全退缩组(Non-pCR)。分别分析CEA、CA199、CA724在新辅助化疗前水平和化疗前后变化量对胃癌新辅助化疗疗效和病理完全缓解率的预测。结果：CEA阳性率与肿瘤的分化程度、淋巴结转移、疾病进展有关。CA724与肿瘤大小、TNM分期等因素相关。3种肿瘤标记物联合检测阳性与淋巴结转移、分化程度密切相关。CEA化疗前高水平对疾病进展可能具有预测作用(AUC = 682, 95%CI: 0.549~0.815, P = 0.010)，最大化该试验的灵敏度(52.2%)和特异性(83.6%)的临界值为17.65 ng/ml。新辅助化疗后3种传统肿瘤标记物的水平较化疗前下降，CA724的降低量可能具有预测疾病控制的作用(AUC = 0.749, 95%CI: 0.550~0.947, P = 0.047)，同时使试验的灵敏度(56.0%)和特异性(85.7%)最大化的最佳截止值降低了64.0%。CA199化疗前水平对非病理完全缓解可能具有预测作用(AUC = 0.740, 95%CI: 0.538~0.942, P = 0.036)，最大化该试验的灵敏度(74.7%)和特异性(85.7%)的临界值为6.89 U/ml。CA724的降低量对病理完全缓解可能具有预测作用(AUC = 0.933, 95%CI: 0.839~1.000, P = 0.043)，同时使试验的灵敏度(100%)和特异性(90.0%)最大化的最佳截止值降低了90.6%。结论：CEA、CA199、CA724可能对胃癌新辅助化疗的疗效和病理反应具有预测作用，对于胃癌的新辅助化疗可能具有指导作用。</p></sec><sec id="s2"><title>关键词</title><p>胃癌，新辅助化疗，疗效评估，CEA，CA199，CA724</p></sec><sec id="s3"><title>Study on Prediction of Neoadjuvant Chemotherapy Efficacy of Traditional Tumor Markers in Gastric Cancer<sup> </sup></title><p>Chuanxu Liu<sup>*</sup>, Xixun Wang, Jinchen Hu, Yifei Zhang, Zengwu Yao, Lixin Jiang<sup>#</sup></p><p>The First Department of Gastrointestinal Surgery, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai Shandong</p><p><img src="//html.hanspub.org/file/1-1572408x5_hanspub.png?20210802170840081" /></p><p>Received: Jun. 19<sup>th</sup>, 2021; accepted: Jul. 25<sup>th</sup>, 2021; published: Aug. 2<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/1-1572408x6_hanspub.png?20210802170840081" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the efficacy of traditional tumor markers in predicting neoadjuvant chemotherapy for gastric cancer. Methods: The clinicopathological data of 90 patients with gastric cancer who received neoadjuvant chemotherapy were retrospectively analyzed. The expression levels of CEA, CA199, and CA724 before and after neoadjuvant chemotherapy were recorded. After neoadjuvant chemotherapy and surgery, the patients were divided according to the recest1.1 scoring standard. For the disease control group (CR + PR + SD) and the disease progression group (PD), patients were divided into pathological complete remission group (pCR) and non-pathological complete remission group (Non-pCR) according to Ryan standard. The levels of CEA, CA199, and CA724 before and after neoadjuvant chemotherapy were analyzed respectively to predict the efficacy of neoadjuvant chemotherapy and pathological complete remission rate for gastric cancer. Results: The positive rate of CEA is related to the degree of tumor differentiation, lymph node metastasis, and disease progression. CA724 is related to tumor size, TNM stage and other factors. The positive combined detection of the three tumor markers is closely related to the degree of lymph node metastasis and differentiation. The high level of CEA before chemotherapy may have a predictive effect on disease progression (AUC = 682, 95%CI: 0.549~0.815, P = 0.010), maximizing the critical value of the sensitivity (52.2%) and specificity (83.6%) of the test, it is 17.65 ng/ml. The levels of the three traditional tumor markers after neoadjuvant chemotherapy were lower than before chemotherapy. The reduction of CA724 may have a predictive effect on disease control (AUC = 0.749, 95%CI: 0.550~0.947, P = 0.047). The optimal cutoff value for maximizing sensitivity (56.0%) and specificity (85.7%) is reduced by 64.0%. The level of CA199 before chemotherapy may have a predictive effect on non-pathological complete remission (AUC = 0.740, 95%CI: 0.538~0.942, P = 0.036), maximizing the sensitivity (74.7%) and specificity (85.7%) of the test, the value is 6.89 U/ml. The reduction of CA724 may have a predictive effect on pathological complete remission (AUC = 0.933, 95%CI: 0.839~1.000, P = 0.043), while maximizing the sensitivity (100%) and specificity (90.0%) of the test, the best cut-off value is reduced by 90.6%. Conclusion: CEA, CA199, and CA724 may have predictive effects on the efficacy and pathological response of neoadjuvant chemotherapy for gastric cancer, and may have a guiding role for neoadjuvant chemotherapy for gastric cancer.</p><p>Keywords:Gastric Cancer, Neoadjuvant Chemotherapy, Evaluations of Response, CEA, CA199, CA724</p><disp-formula id="hanspub.44288-formula4"><graphic xlink:href="//html.hanspub.org/file/1-1572408x7_hanspub.png?20210802170840081"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1572408x8_hanspub.png?20210802170840081" /> <img src="//html.hanspub.org/file/1-1572408x9_hanspub.png?20210802170840081" /></p></sec><sec id="s5"><title>1. 引言</title><p>胃癌是我国也是世界上最常见的恶性肿瘤之一，严重危害人类的生存健康。近年来由于胃癌检查手段和治疗手段的提高，胃癌的发病率和死亡率逐步下降，但仍然是全球癌症死亡第四大原因 [<xref ref-type="bibr" rid="hanspub.44288-ref1">1</xref>]，胃癌仍是威胁人类健康的主要恶性肿瘤之一，尤其是晚期胃癌的五年生存率仍然比较低 [<xref ref-type="bibr" rid="hanspub.44288-ref2">2</xref>]，这与胃癌传统肿瘤标记物的灵敏度和特异度是分不开的。CEA、CA199、CA724作为胃癌密切相关的传统肿瘤标记物，不仅对早期胃癌具有诊断价值，而且对检测复发和远处转移、预测患者生存率和术后监测是有用的 [<xref ref-type="bibr" rid="hanspub.44288-ref3">3</xref>]。新辅助化疗有助于降低肿瘤分期，并可能降低总体死亡率 [<xref ref-type="bibr" rid="hanspub.44288-ref4">4</xref>]，越来越多的胃癌患者从中收益。本研究主要对CEA、CA199、CA724传统肿瘤标记物对新辅助化疗疗效及病理反应的关系进行研究，揭露3种传统肿瘤标记物预测胃癌新辅助化疗疗效的作用。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>本研究共纳入2014年1月至2021年1月于青岛大学附属烟台毓璜顶医院就诊的共90例进展期胃癌患者，均接受新辅助化疗和根治性手术，其中男性69例，女性21例；年龄38~78岁，平均年龄63岁。</p></sec><sec id="s6_2"><title>2.2. 纳入和排除标准</title><p>纳入标准：① T3-4aN + M0的进展期胃癌患者；② 所有患者均是首次诊断胃癌，经胃镜及术后病理活检确诊为胃癌；③ 入院前未行任何治疗；④ 既往无其他恶性肿瘤史；⑤ 临床资料完整者。</p><p>排除标准：① 早期或晚期胃癌患者；② 合并其他系统恶性肿瘤；③ 既往有其他肿瘤病史；④ 复发后再治疗及非肿瘤因素死亡的患者；⑤ 临床病理资料不全。</p></sec><sec id="s6_3"><title>2.3. 疗效评估</title><p>在新辅助化疗前后，所有患者都要进行传统肿瘤标记物水平检测。腹部的计算机断层扫描或核磁共振图像被用来确定胃恶性肿瘤的侵犯程度。正电子发射断层扫描排除任何远处转移。新辅助化疗及手术结束后，根据recist1.1评分标准，分为疾病控制组(CR + PR + SD)和疾病进展组(PD)，肿瘤化疗后病理反应根据肿瘤回归分级(tumor regression grading)，采用Ryan标准：0：无肿瘤残留(完全退缩)；1：仅见少量或单个癌细胞残留；2：肿瘤退缩但有部分残留；3：表示肿瘤无退缩。根据TRG分级将TRG0分为pCR (病理完全缓解)；TRG1-3分为Non-pCR (非病理完全缓解)。</p></sec><sec id="s6_4"><title>2.4. 研究方法</title><p>收集患者以下资料：① 一般资料：年龄、性别；② 临床病理资料：肿瘤的分化程度(参照日本《胃癌处理规约》第15版规定)、肿瘤直径、Borrmann分型、浸润深度、淋巴结转移、TNM分期、脉管癌栓情况、神经浸润、肿瘤部位等。</p><p>在患者入院未行任何治疗前，于清晨空腹状态下抽取患者血液并于2小时之内检测患者外周血中CEA、CA199、CA724的水平，治疗前完善胃镜、超声、多层螺旋CT或磁共振等检查，化疗方案为XELOX或SOX方案，完成2~4周期化疗。在新辅助化疗完成2~4周期后行胃癌根治术并评估患者治疗疗效，并再次检测并记录外周血中CEA、CA199、CA724的水平。</p></sec><sec id="s6_5"><title>2.5. 统计方法</title><p>应用IBMSPSS 25.0统计软件进行统计分析。计数资料的单因素分析采用χ<sup>2</sup>检验或Fisher确切概率法；采用配对样本t检验对配对计量资料进行分析；采用独立样本t检验对计量资料进行分析；构建ROC曲线对3种传统肿瘤标记物的表达水平与化疗疗效和肿瘤病理反应的相关性进行分析。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 癌胚抗原、CA199、CA724的阳性率与胃癌临床病理因素的关系</title><p>癌胚抗原、CA19-9和CA72-4的化疗前水平分别在46.6%、23.3%和35.5%的病例中高于临界值。共有63名患者对一种或多种肿瘤标志物呈阳性(总敏感度：70.0%)。表1显示了肿瘤标志物在新辅助化疗前水平和不同临床病理参数之间的相关性。表1显示，癌胚抗原阳性率可能与肿瘤的分化程度、淋巴结转移、疾病进展有关。CA199阳性率可能与神经浸润相关。CA724阳性率可能与肿瘤大小、TNM分期等因素相关。3种肿瘤标记物联合检测阳性与淋巴结转移、分化程度密切相关。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The relationship between the status of tumor markers before treatment and clinicopathological parameter</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >数量</th><th align="center" valign="middle" >癌胚抗原 (+) N (%)</th><th align="center" valign="middle" >P value</th><th align="center" valign="middle" >CA199 (+) N (%)</th><th align="center" valign="middle" >P value</th><th align="center" valign="middle" >CA72-4 (+) N (%)</th><th align="center" valign="middle" >P value</th><th align="center" valign="middle" >Combined detection (+) N (%)</th><th align="center" valign="middle" >P value</th></tr></thead><tr><td align="center" valign="middle" >性别：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >34 (49.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >18 (26.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >23 (33.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >48 (69.5)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >8 (38)</td><td align="center" valign="middle" >0.369</td><td align="center" valign="middle" >5 (23.8)</td><td align="center" valign="middle" >0.834</td><td align="center" valign="middle" >9 (42.8)</td><td align="center" valign="middle" >0.425</td><td align="center" valign="middle" >15 (71.4)</td><td align="center" valign="middle" >0.870</td></tr><tr><td align="center" valign="middle" >年龄(岁)：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤60</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >18 (52.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >9 (26.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14 (41.1)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >26 (76.4)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;60</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >24 (42.8)</td><td align="center" valign="middle" >0.353</td><td align="center" valign="middle" >14 (25.0)</td><td align="center" valign="middle" >0.877</td><td align="center" valign="middle" >18 (32.1)</td><td align="center" valign="middle" >0.385</td><td align="center" valign="middle" >37 (66.0)</td><td align="center" valign="middle" >0.297</td></tr><tr><td align="center" valign="middle" >分化程度：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >分化较好</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >11 (28.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7 (18.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10 (26.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >22 (57.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >分化不良</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >31 (59.6)</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" >16 (30.7)</td><td align="center" valign="middle" >0.185</td><td align="center" valign="middle" >22 (42.3)</td><td align="center" valign="middle" >0.117</td><td align="center" valign="middle" >41 (78.8)</td><td align="center" valign="middle" >0.032</td></tr><tr><td align="center" valign="middle" >肿瘤直径：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤4 cm</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >36 (45.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >22 (27.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >25 (31.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >55 (68.7)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;4 cm</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >6 (60)</td><td align="center" valign="middle" >0.575</td><td align="center" valign="middle" >1 (10)</td><td align="center" valign="middle" >0.417</td><td align="center" valign="middle" >7 (70)</td><td align="center" valign="middle" >0.039</td><td align="center" valign="middle" >8 (80)</td><td align="center" valign="middle" >0.714</td></tr><tr><td align="center" valign="middle" >浸润深度：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T1 + T2</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >13 (36.1)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >6 (16.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14 (38.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >22 (61.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T3 + T4</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >29 (53.7)</td><td align="center" valign="middle" >0.101</td><td align="center" valign="middle" >17 (31.4)</td><td align="center" valign="middle" >0.114</td><td align="center" valign="middle" >18 (33.3)</td><td align="center" valign="middle" >0.590</td><td align="center" valign="middle" >41 (75.9)</td><td align="center" valign="middle" >0.133</td></tr><tr><td align="center" valign="middle" >淋巴结转移数：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N0 + N1</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >18 (36.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10 (20.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >15 (30.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >29 (59.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N2 + N3</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >24 (58.5)</td><td align="center" valign="middle" >0.039</td><td align="center" valign="middle" >13 (31.7)</td><td align="center" valign="middle" >0.221</td><td align="center" valign="middle" >17 (41.4)</td><td align="center" valign="middle" >0.284</td><td align="center" valign="middle" >34 (82.9)</td><td align="center" valign="middle" >0.014</td></tr><tr><td align="center" valign="middle" >TNM分期：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I + II</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >12 (35.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5 (14.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7 (20.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20 (58.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III + IV</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >30 (53.5)</td><td align="center" valign="middle" >0.092</td><td align="center" valign="middle" >18 (32.1)</td><td align="center" valign="middle" >0.066</td><td align="center" valign="middle" >25 (44.6)</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" >43 (76.7)</td><td align="center" valign="middle" >0.071</td></tr><tr><td align="center" valign="middle" >脉管癌栓：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >10 (43.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5 (21.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10 (43.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >16 (69.5)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >32 (47.7)</td><td align="center" valign="middle" >0.722</td><td align="center" valign="middle" >18 (26.8)</td><td align="center" valign="middle" >0.627</td><td align="center" valign="middle" >22 (32.8)</td><td align="center" valign="middle" >0.358</td><td align="center" valign="middle" >47 (70.1)</td><td align="center" valign="middle" >0.958</td></tr><tr><td align="center" valign="middle" >神经浸润：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >10 (47.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >9 (42.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8 (38.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >17 (80.9)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >32 (46.3)</td><td align="center" valign="middle" >0.920</td><td align="center" valign="middle" >14 (20.2)</td><td align="center" valign="middle" >0.038</td><td align="center" valign="middle" >24 (34.7)</td><td align="center" valign="middle" >0.781</td><td align="center" valign="middle" >46 (66.2)</td><td align="center" valign="middle" >0.211</td></tr><tr><td align="center" valign="middle" >肿瘤部位：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >胃窦</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >28 (51.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >15 (27.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >21 (38.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >36 (66.6)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >胃体 + 胃底</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >14 (38.8)</td><td align="center" valign="middle" >0.227</td><td align="center" valign="middle" >8 (22.2)</td><td align="center" valign="middle" >0.554</td><td align="center" valign="middle" >11 (30.5)</td><td align="center" valign="middle" >0.418</td><td align="center" valign="middle" >27 (75.0)</td><td align="center" valign="middle" >0.398</td></tr><tr><td align="center" valign="middle" >化疗疗效：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CR + PR + SD</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >26 (38.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >17 (25.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >25 (37.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >44 (65.6)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >PD</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >16 (69.5)</td><td align="center" valign="middle" >0.011</td><td align="center" valign="middle" >6 (26.0)</td><td align="center" valign="middle" >0.946</td><td align="center" valign="middle" >7 (30.4)</td><td align="center" valign="middle" >0.552</td><td align="center" valign="middle" >19 (82.6)</td><td align="center" valign="middle" >0.126</td></tr><tr><td align="center" valign="middle" >病理反应：</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >pCR</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >5 (71.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1 (14.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2 (28.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >6 (85.7)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Non-pCR</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >37 (44.5)</td><td align="center" valign="middle" >0.245</td><td align="center" valign="middle" >22 (26.5)</td><td align="center" valign="middle" >0.794</td><td align="center" valign="middle" >30 (36.1)</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >57 (68.6)</td><td align="center" valign="middle" >0.670</td></tr></tbody></table></table-wrap><p>表1. 肿瘤标志物治疗前状态与临床病理参数的关系</p><p>注：CEA正常值参考范围：0~5.0 ng/ml；CA199正常值参考范围：0~39.0 Uml；CA724正常值参考范围：0~6.9 U/ml。Combined detection (+)：联合检测阳性是指癌胚抗原、CA199、CA724中任意一种或多种阳性即称为联合检测阳性，仅当癌胚抗原、CA199、CA724均为阴性的时候称为联合检测阴性。CR：完全缓解。PR：部分缓解。SD：无明显缓解或进展。PD：疾病进展。pCR：病理完全退缩。Non-pCR：非病理完全退缩。将高、中分化乳头状腺癌和管状腺癌归为分化良好，低分化腺癌、印戒细胞癌、粘液腺癌和未分化癌归为分化不良。</p></sec><sec id="s7_2"><title>3.2. 化疗前癌胚抗原、CA199、CA724的表达水平预测疾病进展</title>化疗前癌胚抗原、CA199、CA724的表达水平与疾病进展构建ROC曲线<p>图1. 癌胚抗原</p><p>图2. CA199</p><p>图3. CA724</p><p>癌胚抗原、CA199、CA724在化疗前的表达水平预测新辅助化疗后疾病进展的ROC曲线。癌胚抗原化疗前水平的ROC曲线下面积为0.682 (95%置信区间：0.549~0.815，P = 0.010)；最大化该试验的灵敏度(52.2%)和特异性(83.6%)的临界值为17.65 ng/ml。图2、图3显示CA199、CA72-4的预处理水平无统计学意义(P值分别为0.711和0.263) (图1、图2、图3)。</p></sec><sec id="s7_3"><title>3.3. 化疗前后癌胚抗原、CA199、CA724的变化与新辅助化疗疗效的关系</title><sec id="s7_3_1"><title>3.3.1. 化疗前后癌胚抗原、CA199、CA724的变化趋势</title><p>图4. 癌胚抗原</p><p>图5. CA199</p><p>图6. CA724</p><p>癌胚抗原、CA199、CA724分别在新辅助化疗前后进行配对样本t检验，结果发现表达量均有所下降(如图4、图5、图6)，其中癌胚抗原和CA199下降明显，具有统计学差异(P值分别为0.009和0.004)。CA724虽有下降趋势，但没有统计学意义(P = 0.194)。</p></sec><sec id="s7_3_2"><title>3.3.2. 化疗前后癌胚抗原、CA199、CA724的降低量与新辅助化疗疗效之间的关系</title><p>图7. 癌胚抗原</p><p>图8. CA199</p><p>图9. CA724</p><p>对疾病控制组和疾病进展组中癌胚抗原、CA199、CA724的下降量进行独立样本t检验，结果发现癌胚抗原、CA199的下降量在疾病控制组和疾病进展组中无明显差异(P值分别为0.986和0.574)。CA724的下降量在疾病控制组中明显高于疾病进展组，甚至CA724在疾病进展组中呈升高趋势，差异有统计学意义(P = 0.31) (图7、图8、图9)。</p></sec></sec><sec id="s7_4"><title>3.4. 化疗前后癌胚抗原、CA199、CA724的降低量预测疾病控制</title><sec id="s7_4_1"><title>3种肿瘤标志物降低量预测新辅助化疗后疾病控制的ROC曲线</title><p>预测新辅助化疗后疾病控制的3种肿瘤标志物降低量的ROC曲线。分别选取接受化疗前CEA、CA199、CA724是阳性的患者，对其化疗前后的降低量与疾病控制构建ROC曲线，显示CEA、CA199的降低与疾病控制无统计学意义(P值分别为0.897和0.889)。CA724变化值的ROC曲线下面积为0.749 (95%置信区间：0.550~0.947，P = 0.047)；同时使试验的灵敏度(56.0%)和特异性(85.7%)最大化的最佳截止值降低了64.0% (图10、图11、图12)。</p><p>图10. 癌胚抗原</p><p>图11. CA199</p><p>图12. CA724</p></sec></sec><sec id="s7_5"><title>3.5. 化疗前癌胚抗原、CA199、CA724的表达水平预测Non-pCR</title>化疗前3种肿瘤标记物的表达水平与术后Non-pCR关系的ROC曲线<p>癌胚抗原、CA199、CA724肿瘤标志物化疗前水平预测非pCR的ROC曲线。CA199化疗前水平的ROC曲线下面积为0.740 (95%置信区间：0.538~0.942，P = 0.036)；最大化该试验的灵敏度(74.7%)和特异性(85.7%)的临界值为6.89 U/ml。图2、图3显示癌胚抗原、CA724的预处理水平无统计学意义(P值分别为0.231和0.922) (图13、图14、图15)。</p><p>图13. 癌胚抗原</p><p>图14. CA199</p><p>图15. CA724</p></sec><sec id="s7_6"><title>3.6. 化疗前后癌胚抗原、CA199、CA724的降低量预测pCR</title>化疗前后3种肿瘤标记物降低量与术后pCR的ROC曲线<p>预测新辅助化疗后pCR与3种肿瘤标志物降低量的ROC曲线。分别选取接受化疗前癌胚抗原、CA199、CA724是阳性的患者，对其化疗前后的降低量与疾病控制构建ROC曲线，显示癌胚抗原、CA199的降低与疾病控制无统计学意义(P值分别为0.627和0.291)。CA724变化值的ROC曲线下面积为0.933 (95%置信区间：0.839~1.000，P = 0.043)；同时使试验的灵敏度(100%)和特异性(90.0%)最大化的最佳截止值降低了90.6% (图16、图17、图18)。</p><p>图16. 癌胚抗原</p><p>图17. CA199</p><p>图18. CA724</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>随着现代生活的发展，人类的生活环境与生活方式发生了巨大的改变，不规则饮食、抽烟喝酒、电离辐射和特殊职业暴露等胃癌风险因素导致了胃癌发病率居高不下 [<xref ref-type="bibr" rid="hanspub.44288-ref5">5</xref>]。很多患者在胃癌早期往往症状不明显，大多数就诊时已经处于疾病中晚期。术前进行新辅助化疗可以使肿瘤缩小，降低了肿瘤分期、减少脉管癌栓和神经浸润的阳性率，术后并发症和住院时间也随之减少 [<xref ref-type="bibr" rid="hanspub.44288-ref6">6</xref>]，越来越多的患者在新辅助化疗中所收益。外周血清中的肿瘤标记物癌胚抗原、CA199、CA724是与胃癌密切相关的，不仅具有易获得的特点，而且癌胚抗原、CA19-9和CA72-4的组合是手术或化疗前分期的有效方法，特别是监测手术或化疗前升高的肿瘤标记物可能有助于检测复发或评估反应 [<xref ref-type="bibr" rid="hanspub.44288-ref3">3</xref>]。在新辅助化疗的临床应用中，反应标记非常重要，关于这一方面的研究已经有不少报道表明术前肿瘤标记物水平与预后相关 [<xref ref-type="bibr" rid="hanspub.44288-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44288-ref8">8</xref>]。为了监测新辅助化疗过程中的临床疗效及病理反应，我们注重分析化疗前后传统肿瘤标记物癌胚抗原、CA199、CA724之间的变化。</p><p>作为胃癌的传统肿瘤标记物，癌胚抗原、CA199、CA724均具有诊断价值，其在90名患者中的阳性率分别为46.6%、23.3%和35.5%。共有63名患者对一种或多种肿瘤标志物呈阳性(总阳性率：70.0%)。通过卡方检验分析，化疗前癌胚抗原阳性率与肿瘤的分化程度、淋巴结转移、疾病进展有关。CA724与肿瘤大小、TNM分期等因素相关。Jia等人对322名晚期胃癌患者进行分析，发现血清癌胚抗原和CA19-9 的表达水平与肿瘤入侵、淋巴结转移和TNM阶段(所有P &lt; 0.05)密切相关 [<xref ref-type="bibr" rid="hanspub.44288-ref9">9</xref>]。Tong等人通过对290名接受新辅助化疗和D2根治手术的胃癌患者进行回顾性分析，发现化疗前CA199和CA724水平与淋巴结转移和TNM分期有关 [<xref ref-type="bibr" rid="hanspub.44288-ref8">8</xref>]。不同中心研究的结果不尽相同，这可能与地区不同、样本量差异、检测技术不一样有关。</p><p>在新辅助化疗和手术结束后，根据recist1.1评分标准将化疗疗效分为疾病控制组和疾病进展组。通过对化疗前3肿瘤标记物的水平与化疗后疾病进展构建ROC曲线，结果分析化疗前癌胚抗原水平与疾病进展密切相关(P = 0.010)，高癌胚抗原水平(+17.65 ng/ml)化疗疗效较差。化疗前CA199 (P = 0.711)、CA724 (P = 0.263)与疾病进展无明确相关。一项对184名接受FOLFOX方案新辅助化疗的胃癌患者进行回顾性分析表明，高术前癌胚抗原水平(+50 ng/ml)可预测新辅助化疗后的临床疾病进展 [<xref ref-type="bibr" rid="hanspub.44288-ref7">7</xref>]。临界值不同可能与化疗方案、样本量差异产生的偏倚有关。同样，传统肿瘤标记物对化疗疗效的预测不仅体现在新辅助化疗的患者，在其他接受化疗的患者身上也体现出传统肿瘤标记物具有化疗疗效的预测作用。在一项评估传统肿瘤标记物监测胃癌姑息化疗疗效的研究中发现，化疗前癌胚抗原和CA199的高水平与疾病进展和不良预后呈正相关 [<xref ref-type="bibr" rid="hanspub.44288-ref10">10</xref>]。化疗前CA724的水平与新辅助化疗疗效的关系暂不清楚，但已有研究表明化疗CA724的高水平可以预测腹膜转移 [<xref ref-type="bibr" rid="hanspub.44288-ref11">11</xref>]。</p><p>本研究通过配对样本t检验发现，新辅助化疗前后3种肿瘤标记物的表达水平均有不同程度的下降，其中癌胚抗原、CA199的下降量在疾病控制组和疾病进展组中无明显差异，CA724在两组之间显著不同。一些研究表明，传统肿瘤标记物变化的测量可能有助于监测胃癌患者对化疗的反应，肿瘤减少与患者血清癌胚抗原的减少之间有显著的相关性 [<xref ref-type="bibr" rid="hanspub.44288-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.44288-ref13">13</xref>]。本研究分别在3种肿瘤标记物阳性的患者中分析标记物化疗前后变化与疾病控制的关系，结果表明CA724的下降与疾病控制相关，当CA724下降了化疗前水平的64.0%及以上的时候，可使预测疾病控制的灵敏度(56.0%)和特异性(85.7%)达到最大化。一项评估晚期胃癌化疗期间CA724血清水平下降预测化疗疗效的研究表明，CA724血清水平的下降似乎可以预测晚期胃癌化疗的疗效，构建ROC曲线后确定CA724血清水平减少的最佳截止值为20.5% [<xref ref-type="bibr" rid="hanspub.44288-ref14">14</xref>]。</p><p>术前化疗后的TRG是胃腺癌患者的一个重要预后因素，它反映了新辅助化疗后切除标本组织形态评价的重要分级标准，主要用于评估肿瘤组织纤维化程度和残留肿瘤细胞比例，而病理反应是生存率较差的一个独立预测因素 [<xref ref-type="bibr" rid="hanspub.44288-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.44288-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.44288-ref17">17</xref>]。pCR是指经过新辅助化疗之后，术后病理未发现原发性肿瘤细胞。已有研究表明，pCR的患者比Non-pCR的患者预后要好 [<xref ref-type="bibr" rid="hanspub.44288-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.44288-ref18">18</xref>]，所以本研究对新辅助化疗手术后的病理数据进行了收集，采用TRG分级并分析传统肿瘤标记物能否对新辅助化疗后的肿瘤病理反应进行预测。本研究发现，化疗前CA199的水平能够预测肿瘤的病理反应，化疗前CA199水平越高，肿瘤病理达到完全缓解的几率就越小。一项研究曾对新辅助化疗后胃癌的病理完全缓解构建预测模型，结果发现治疗前临床分期、CA199水平、肿瘤最长径及治疗模式是胃癌新辅助化疗达到完全缓解的影响因素 [<xref ref-type="bibr" rid="hanspub.44288-ref19">19</xref>]。由此可见，CA199可能与患者对新辅助化疗的敏感性有关，因新辅助化疗前监测患者CA199的表达水平，可能预测新辅助化疗的病理反应，从而为患者是否行新辅助化疗及决定化疗方案提供了参考。本研究选取了新辅助化疗前传统肿瘤标记物阳性的患者，观察标记物前后变化与病理反应的关系。结果发现CA724的降低量可能与病理完全缓解有关，但经过筛选新辅助化疗前传统肿瘤标记物阳性的病理完全患者的患者较少，所以新辅助化疗前后传统肿瘤标记物变化量与病理反应的关系有待进一步研究。但已有研究发现CA72-4的下降(+70%)可能预测对新辅助化疗的病理反应 [<xref ref-type="bibr" rid="hanspub.44288-ref7">7</xref>]。因此可以通过观察新辅助化疗前后CA724水平的变化来预测新辅助治疗的病理反应，并决定是否继续化疗或更改治疗方案。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，传统肿瘤标记物癌胚抗原、CA199、CA724可能对新辅助化疗的疗效具有预测作用，结合新辅助治疗前和治疗后肿瘤标记物的变化，可能有助于更好地判断新辅助化疗的疗效，从而指导胃癌患者的进一步诊疗。</p></sec><sec id="s10"><title>利益冲突</title><p>所有作者均声明不存在利益冲突。</p><p>该实验获得医院伦理委员会批准，获得患者的知情同意并签署知情同意书。</p></sec><sec id="s11"><title>基金项目</title><p>山东大学项目(3460019005)；烟台市科技发展计划(2019MSGY136)。</p></sec><sec id="s12"><title>文章引用</title><p>刘传绪,王熙勋,胡金晨,张翼飞,姚增武,姜立新. 传统肿瘤标记物预测胃癌新辅助化疗疗效的研究Study on Prediction of Neoadjuvant Chemotherapy Efficacy of Traditional Tumor Markers in Gastric Cancer[J]. 临床医学进展, 2021, 11(08): 3333-3348. https://doi.org/10.12677/ACM.2021.118484</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44288-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Machlowska, J., Baj, J., Sitarz, M., et al. (2020) Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. International Journal of Molecular Sciences, 21, E4012.  
&lt;br&gt;https://doi.org/10.3390/ijms21114012</mixed-citation></ref><ref id="hanspub.44288-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">本刊编辑部. 《中国肿瘤临床》文章荐读: 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2018, 45(6): 60.</mixed-citation></ref><ref id="hanspub.44288-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Shimada, H., Noie, T., Ohashi, M., et al. (2014) Clinical Significance of Serum Tumor Markers for Gastric Cancer: A Systematic Review of Literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 17, 26-33. &lt;br&gt;https://doi.org/10.1007/s10120-013-0259-5</mixed-citation></ref><ref id="hanspub.44288-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Xu, A.M., Huang, L., Liu, W., et al. (2014) Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Gastric Carcinoma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 9, e86941.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0086941</mixed-citation></ref><ref id="hanspub.44288-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yusefi, A.R., Bagheri Lankarani, K., Bastani, P., et al. (2018) Risk Factors for Gastric Cancer: A Systematic Review. Asian Pacific Journal of Cancer Prevention, 19, 591-603.</mixed-citation></ref><ref id="hanspub.44288-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Charruf, A.Z., Ramos, M.F.K.P., Pereira, M.A., et al. (2020) Impact of Neoadjuvant Chemotherapy on Surgical and Pathological Results of Gastric Cancer Patients: A Case-Control Study. Journal of Surgical Oncology, 121, 833-839.  
&lt;br&gt;https://doi.org/10.1002/jso.25839</mixed-citation></ref><ref id="hanspub.44288-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Z. and Zhang, N. (2014) Clinical Evaluation of CEA, CA19-9, CA72-4 and CA125 in Gastric Cancer Patients with Neoadjuvant Chemotherapy. World Journal of Surgical Oncology, 12, 397.  
&lt;br&gt;https://doi.org/10.1186/1477-7819-12-397</mixed-citation></ref><ref id="hanspub.44288-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Tong, Y., Zhao, Y., Shan, Z., et al. (2021) CA724 Predicts Overall Survival in Locally Advanced Gastric Cancer Patients with Neoadjuvant Chemotherapy. BMC Cancer, 21, 4. &lt;br&gt;https://doi.org/10.1186/s12885-020-07666-8</mixed-citation></ref><ref id="hanspub.44288-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.H., Mai, C., Hong, J., et al. (2012) Predicting Value of Serum CEA and CA19-9 in Neoadjuvant Chemotherapy for Advanced Gastric Carcinoma. Chinese Journal of Gastrointestinal Surgery, 15, 1273-1276. (In Chinese)</mixed-citation></ref><ref id="hanspub.44288-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Abbas, M., Ahmed, A., Khan, G.J., et al. (2019) Clinical Evaluation of Carcinoembryonic and Carbohydrate Antigens as Cancer Biomarkers to Monitor Palliative Chemotherapy in Advanced Stage Gastric Cancer. Current Problems in Cancer, 43, 5-17. &lt;br&gt;https://doi.org/10.1016/j.currproblcancer.2018.08.003</mixed-citation></ref><ref id="hanspub.44288-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Emoto, S., Ishigami, H., Yamashita, H., et al. (2012) Clinical Significance of CA125 and CA72-4 in Gastric Cancer with Peritoneal Dissemination. Gastric Cancer, 15, 154-161. &lt;br&gt;https://doi.org/10.1007/s10120-011-0091-8</mixed-citation></ref><ref id="hanspub.44288-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Imamura, Y., Yasutake, K., Yoshimura, Y., et al. (1990) The Changes in Tumor Markers Such as Serum CEA, CA 19-9, TPA and CA125 in the Chemotherapy of Patients with Advanced Gastric Cancer. Japanese Journal of Cancer and Chemotherapy, 17, 1501-1507.</mixed-citation></ref><ref id="hanspub.44288-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Caponetti, R., Caponetti, T. and Vici, P. (2002) Changes in Tumor Markers CEA, Ca 19-9 and Ca 125 in Monitoring of Response to Chemotherapy in Elderly Patients with Advanced Gastric Cancer. Clinical Therapeutics, 153, 373-375. (In Italian).</mixed-citation></ref><ref id="hanspub.44288-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zou, L. and Qian, J. (2014) Decline of Serum CA724 as a Probable Predictive Factor for Tumor Response during Chemotherapy of Advanced Gastric Carcinoma. Chinese Journal of Cancer Research, 26, 404-409.</mixed-citation></ref><ref id="hanspub.44288-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Derieux, S., Svrcek, M., Manela, S., et al. (2020) Evaluation of the Prognostic Impact of Pathologic Response to Preoperative Chemotherapy Using Mandard’s Tumor Regression Grade (TRG) in Gastric Adenocarcinoma. Digestive and Liver Disease, 52, 107-114. &lt;br&gt;https://doi.org/10.1016/j.dld.2019.07.010</mixed-citation></ref><ref id="hanspub.44288-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ma, Q. and Yuan, F. (2018) Pathological Evaluation System for Preoperative Treatment of Gastric Cancer. Chinese Journal of Gastrointestinal Surgery, 21, 1121-1124. (In Chinese)</mixed-citation></ref><ref id="hanspub.44288-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Xu, X., Zheng, G., Zhang, T., et al. (2019) Is Pathologic Tumor Regression Grade after Neo-Adjuvant Chemotherapy a Promising Prognostic Indicator for Patients with Locally Advanced Gastric Cancer? A Cohort Study Evaluating Tumor Regression Response. Cancer Chemotherapy and Pharmacology, 84, 635-646.  
&lt;br&gt;https://doi.org/10.1007/s00280-019-03893-4</mixed-citation></ref><ref id="hanspub.44288-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Koh, Y.W., Park, Y.S., Ryu, M.H., et al. (2013) Postoperative Nodal Status and Diffuse-Type Histology Are Independent Prognostic Factors in Resectable Advanced Gastric Carcinomas after Preoperative Chemotherapy. The American Journal of Surgical Pathology, 37, 1022-1029. &lt;br&gt;https://doi.org/10.1097/PAS.0b013e31828778fd</mixed-citation></ref><ref id="hanspub.44288-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">田园, 杨沛刚, 李勇, 等. 进展期胃癌新辅助治疗后病理完全缓解相关因素分析及风险预测模型建立[J]. 中国肿瘤临床, 2020, 47(16): 829-834.</mixed-citation></ref></ref-list></back></article>